Quanterix (QTRX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
24 Apr, 2026Executive summary
The annual meeting will be held virtually on June 9, 2026, with voting on key proposals including director elections, executive compensation, auditor ratification, and an equity plan amendment.
Only stockholders of record as of April 14, 2026, are eligible to vote, with multiple voting methods available.
The Board recommends voting in favor of all proposals and nominees.
Voting matters and shareholder proposals
Stockholders will vote to elect two directors for one-year terms, approve executive compensation (say-on-pay), ratify KPMG LLP as auditor, and approve the amended 2017 Equity Incentive Plan.
Majority of votes cast is required for approval of each proposal; broker discretionary voting is only permitted for auditor ratification.
Shareholder proposals and director nominations for the 2027 meeting must follow specific deadlines and procedures.
Board of directors and corporate governance
The Board consists of nine members, with a transition to annual elections for all directors by 2028.
Board committees include Audit, Compensation, and Nominating and Governance, each with defined responsibilities and independent membership.
Board leadership includes a Chair and a Lead Independent Director, with annual self-evaluations and robust governance guidelines.
Stock ownership guidelines apply to directors and executives to align interests with shareholders.
Latest events from Quanterix
- Proxy supplement updates equity plan limits and confirms key votes for the 2026 annual meeting.QTRX
Proxy filing8 May 2026 - Q1 2026 revenue up 20% to $36.4M, with improved margins and $85M in cost synergies.QTRX
Q1 20266 May 2026 - Diagnostics and diversification drive growth as financial discipline and innovation strengthen outlook.QTRX
Leerink Global Healthcare Conference 202629 Apr 2026 - Diagnostics and recurring revenue drive growth, with Alzheimer's and Akoya integration as key priorities.QTRX
TD Cowen 46th Annual Health Care Conference4 Mar 2026 - Q4 revenue up 25% year-over-year; 2026 targets include breakeven and strong growth.QTRX
Q4 20252 Mar 2026 - Sustained growth, new platforms, and Akoya integration drive expansion and profitability.QTRX
43rd Annual J.P. Morgan Healthcare Conference 20253 Feb 2026 - Blood-based diagnostics and multi-marker innovation drive growth, margin gains, and future strategy.QTRX
Goldman Sachs 45th Annual Global Healthcare Conference3 Feb 2026 - Q2 revenue up 11% to $34.4M, net loss widened, 2024 outlook lowered amid capital constraints.QTRX
Q2 20242 Feb 2026 - Strong service growth and multiplex assay innovation drive expansion in neurology diagnostics.QTRX
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026